LivaNova (NASDAQ:LIVN) Updates FY 2024 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.050-3.150 for the period, compared to the consensus earnings per share estimate of 3.000. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. LivaNova also updated its FY24 guidance to $3.05-3.15 EPS.

Analysts Set New Price Targets

A number of research firms have weighed in on LIVN. Needham & Company LLC reiterated a buy rating and issued a $72.00 target price on shares of LivaNova in a research note on Wednesday. Mizuho increased their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research note on Thursday. Robert W. Baird increased their target price on shares of LivaNova from $58.00 to $66.00 and gave the stock a neutral rating in a research note on Thursday. Barclays increased their price target on shares of LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a report on Monday, February 26th. Finally, StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $66.20.

LivaNova Price Performance

LIVN stock opened at $64.15 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.51 and a current ratio of 3.17. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.36. The firm’s fifty day moving average is $54.57 and its 200 day moving average is $50.94. The firm has a market cap of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. The business had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 EPS. Research analysts predict that LivaNova will post 3.01 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.